| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DRD3 |
| Uniprot No | P35462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-400aa |
| 氨基酸序列 | MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC |
| 预测分子量 | 44,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DRD3重组蛋白的3篇代表性文献示例，涵盖表达、功能及结构研究：
---
1. **文献名称**：*Expression and Purification of the Human Dopamine D3 Receptor in Mammalian Cells*
**作者**：M. Teeter et al.
**摘要**：本研究报道了在HEK293细胞中稳定表达人源DRD3重组蛋白的方法，采用亲和层析和尺寸排阻色谱纯化获得高纯度蛋白。功能分析显示纯化后的受体保留多巴胺结合活性，并激活下游G蛋白信号通路。
---
2. **文献名称**：*Structural Insights into the Human Dopamine D3 Receptor by Cryo-EM*
**作者**：E. Y. T. Chien et al.
**摘要**：通过杆状病毒-昆虫细胞系统表达DRD3重组蛋白，结合冷冻电镜技术解析其与拮抗剂结合的高分辨率结构，揭示了受体配体结合口袋的构象特征，为靶向药物设计提供结构基础。
---
3. **文献名称**：*Optimization of Recombinant DRD3 Expression in E. coli for Ligand Screening*
**作者**：K. Zhang & L. Wang
**摘要**：探索在大肠杆菌中高效表达DRD3胞外结构域的策略，通过密码子优化和诱导条件优化提高可溶性蛋白产量。纯化后的蛋白成功用于高通量配体筛选，鉴定出新型DRD3拮抗剂。
---
**备注**：以上文献信息为示例性质，具体研究需通过学术数据库(如PubMed、Web of Science)检索最新文章。实际写作时建议引用真实发表的论文。
Dopamine receptor D3 (DRD3), a member of the G protein-coupled receptor (GPCR) family, plays a critical role in regulating dopamine-mediated neurotransmission in the central nervous system. Primarily expressed in limbic regions, DRD3 is implicated in emotional regulation, cognitive function, and reward-seeking behaviors. Its involvement in neuropsychiatric disorders, such as schizophrenia, Parkinson’s disease, and substance addiction, has driven extensive research into its structure, signaling pathways, and therapeutic targeting. Unlike the closely related DRD2 receptor, DRD3 exhibits higher affinity for dopamine and distinct localization, making selective modulation a key focus for drug development to minimize off-target effects.
Recombinant DRD3 protein, engineered through heterologous expression systems (e.g., mammalian cells, insect cells, or *E. coli*), enables detailed biochemical and pharmacological studies. These systems allow production of purified, functional DRD3 proteins with post-translational modifications mimicking native receptors. Researchers utilize recombinant DRD3 to study ligand-receptor interactions, screen potential therapeutics, and dissect downstream signaling cascades (e.g., cAMP inhibition, β-arrestin recruitment). Its soluble extracellular domains are also employed in structural biology (e.g., X-ray crystallography, cryo-EM) to resolve 3D conformations, aiding in the design of subtype-selective drugs.
The development of DRD3-targeted therapies holds promise for treating addiction and movement disorders, but challenges remain in achieving receptor specificity and avoiding side effects. Recombinant DRD3 proteins serve as indispensable tools to address these challenges, bridging molecular insights and clinical applications.
×
